Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2023 | Percentile | Sector n |
|---|---|---|---|---|
| Chachava Clinic | Healthcare Services | 39.6% | 95th pct | 312 |
| Gagua Clinic | Healthcare Services | 20.7% | 78th pct | 312 |
| Jerarsi | Healthcare Services | 20.2% | 78th pct | 312 |
| Israeli-Georgian Medica… | Healthcare Services | 5.8% | 41st pct | 312 |
| Academician Vakhtang Bo… | Healthcare Services | 0.3% | 28th pct | 312 |
Percentile is within each company's own sector across the whole FY2023 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2023 | Chachava Clinic | Israeli-Georgian Medica… | Jerarsi | Gagua Clinic | Academician Vakhtang Bo… |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 87.0% | 28.8% | 74.4% | 83.5% | 77.7% |
| EBITDA Margin | 39.6% | 5.8% | 20.2% | 20.7% | 0.3% |
| EBITDAR | 11,279 | 1,634 | 5,619 | 5,029 | 66 |
| EBITDAR Margin | 39.6% | 5.8% | 20.2% | 20.7% | 0.3% |
| EBIT Margin | 37.0% | 5.8% | 4.1% | 18.0% | -10.8% |
| Net Profit Margin | 43.8% | 8.2% | -6.5% | 16.6% | -10.6% |
| Operating Expense % of Sales | 47.5% | 23.0% | 56.4% | 66.3% | 78.5% |
| Returns | |||||
| Return on Assets (ROA) | 22.4% | 8.4% | -5.5% | 20.2% | -10.1% |
| Return on Equity (ROE) | 24.2% | 29.5% | N/A | 24.2% | -14.2% |
| ROIC [EBIT / Invested Capital] | 31.4% | ||||
| 8.1% |
| 4.6% |
| 23.9% |
| -12.1% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 0.0% | 47.4% | 116.9% | 10.0% | 15.5% |
| Debt-to-Equity | 0.00x | 1.67x | -3.30x | 0.12x | 0.22x |
| Debt-to-EBITDA | 0.00x | 8.00x | 6.81x | 0.40x | 48.21x |
| Equity-to-Assets | 92.5% | 28.4% | -35.4% | 83.2% | 71.3% |
| Net Debt | -18,018 | 12,449 | 36,390 | 1,630 | 2,938 |
| Cash & Equivalents | 18,018 | 616 | 1,871 | 381 | 258 |
| Total Debt | N/A | 13,065 | 38,261 | 2,011 | 3,196 |
| Liquidity & working capital | |||||
| Current Ratio | 5.02x | 1.95x | 0.74x | 1.50x | 2.13x |
| Quick Ratio | 4.68x | 1.45x | 0.62x | 1.33x | 1.78x |
| Cash Ratio | 4.31x | 0.11x | 0.11x | 0.20x | 0.09x |
| Total Current Assets | 21,010 | 10,725 | 12,368 | 2,917 | 6,471 |
| Total Current Liabilities | 4,182 | 5,505 | 16,716 | 1,945 | 3,036 |
| Inventory | 1,451 | 2,757 | 2,027 | 338 | 1,078 |
| Trade Receivables | 1,428 | 7,352 | 8,470 | 2,198 | 5,135 |
| Trade Payables | 1,016 | 4,051 | 6,055 | 1,343 | 2,742 |
| Net Working Capital | 16,828 | 5,220 | -4,348 | 972 | 3,435 |
| Net Working Capital % of Revenue | 59.0% | 18.5% | -15.6% | 4.0% | 17.3% |
| Trade Working Capital | 1,863 | 6,058 | 4,441 | 1,193 | 3,471 |
| Trade Working Capital % of Revenue | 6.5% | 21.5% | 15.9% | 4.9% | 17.5% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | 2.55x | 7.29x | 3.52x | 11.85x | 4.09x |
| Days Inventory Outstanding (DIO) | 143.1 | 50.0 | 103.8 | 30.8 | 89.2 |
| Receivables Turnover | 19.97x | 3.84x | 3.29x | 11.05x | 3.86x |
| Days Sales Outstanding (DSO) | 18.3 | 95.1 | 111.0 | 33.0 | 94.5 |
| Payables Turnover | 3.64x | 4.96x | 1.18x | 2.98x | 1.61x |
| Days Payable Outstanding (DPO) | 100.2 | 73.5 | 310.2 | 122.4 | 226.9 |
| Cash Conversion Cycle | 61.2 days | 71.6 days | -95.4 days | -58.6 days | -43.1 days |
| Asset Turnover | 0.51x | 1.02x | 0.85x | 1.21x | 0.96x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 6,493 | 2,674 | 814 | 3,538 | 1,915 |
| Free Cash Flow (OCF − Capex proxy) | 394 | -1,528 | 923 | 1,610 | 336 |
| Cash Conversion (OCF / EBITDA) | 57.6% | 163.6% | 14.5% | 70.4% | 2888.7% |
| Dividends Declared | 105 | 0 | 0 | 1,701 | 3,800 |
| Dividend Payout Ratio | 0.8% | 0.0% | N/A | 42.1% | N/A |